Literature DB >> 8195618

Detection of Norwalk virus or Norwalk-like virus infections in Finnish infants and young children.

J F Lew1, J Valdesuso, T Vesikari, A Z Kapikian, X Jiang, M K Estes, K Y Green.   

Abstract

Norwalk virus (NV) and Norwalk-like viruses are important causes of epidemic nonbacterial gastroenteritis in older children and adults. Serologic responses to NV of 154 Finnish infants and young children participating in a rotavirus vaccine study were examined by ELISA with a recently available baculovirus-expressed recombinant NV capsid protein. In 4 serially collected sera (at the median ages of 3, 4, 14, and 23 months), 49% of children had at least one NV infection over the approximately 2-year study period. Children with low NV-specific IgG titers (< 1:50) at the median age of 4 or 14 months were significantly more likely to acquire an NV infection by the median age of 14 or 23 months, respectively, than children who had higher NV IgG titers (> 1:50) (P < .05). Thus, NV or Norwalk-like virus infections are more common in infants and young children than previously believed, and antibody to NV may be protective against such infections.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8195618     DOI: 10.1093/infdis/169.6.1364

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Norovirus GII-4 causes a more severe gastroenteritis than other noroviruses in young children.

Authors:  Leena Huhti; Evelin D Szakal; Leena Puustinen; Marjo Salminen; Heini Huhtala; Oona Valve; Vesna Blazevic; Timo Vesikari
Journal:  J Infect Dis       Date:  2011-03-16       Impact factor: 5.226

Review 2.  Diagnosis of noncultivatable gastroenteritis viruses, the human caliciviruses.

Authors:  R L Atmar; M K Estes
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

3.  Characterization of Toronto virus capsid protein expressed in baculovirus.

Authors:  J P Leite; T Ando; J S Noel; B Jiang; C D Humphrey; J F Lew; K Y Green; R I Glass; S S Monroe
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

4.  Epidemiological study of prevalence of genogroup II human calicivirus (Mexico virus) infections in Japan and Southeast Asia as determined by enzyme-linked immunosorbent assays.

Authors:  S Honma; S Nakata; K Numata; K Kogawa; T Yamashita; M Oseto; X Jiang; S Chiba
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

5.  A comparison of methods for purification and concentration of norovirus GII-4 capsid virus-like particles.

Authors:  L Huhti; V Blazevic; K Nurminen; T Koho; V P Hytönen; T Vesikari
Journal:  Arch Virol       Date:  2010-08-19       Impact factor: 2.574

Review 6.  Progress toward norovirus vaccines: considerations for further development and implementation in potential target populations.

Authors:  Negar Aliabadi; Ben A Lopman; Umesh D Parashar; Aron J Hall
Journal:  Expert Rev Vaccines       Date:  2015-07-29       Impact factor: 5.217

7.  Expression, self-assembly, and antigenicity of a snow mountain agent-like calicivirus capsid protein.

Authors:  X Jiang; D O Matson; G M Ruiz-Palacios; J Hu; J Treanor; L K Pickering
Journal:  J Clin Microbiol       Date:  1995-06       Impact factor: 5.948

8.  Two epidemiologic patterns of norovirus outbreaks: surveillance in England and wales, 1992-2000.

Authors:  Benjamin A Lopman; Goutam K Adak; Mark H Reacher; David W G Brown
Journal:  Emerg Infect Dis       Date:  2003-01       Impact factor: 6.883

9.  Prevalence of human calicivirus infections in Kenya as determined by enzyme immunoassays for three genogroups of the virus.

Authors:  S Nakata; S Honma; K Numata; K Kogawa; S Ukae; N Adachi; X Jiang; M K Estes; Z Gatheru; P M Tukei; S Chiba
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

10.  Immune mechanisms responsible for vaccination against and clearance of mucosal and lymphatic norovirus infection.

Authors:  Karen A Chachu; Anna D LoBue; David W Strong; Ralph S Baric; Herbert W Virgin
Journal:  PLoS Pathog       Date:  2008-12-12       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.